ILCA Guidance

HomeEducationILCA Guidance

The past few years have witnessed huge progress in the treatment of advanced HCC and the therapeutic landscape has been transformed. In order to provide comprehensive, up-to-date and readily accessible information about the latest treatment, ILCA have developed on-line guidance. The guidance has been launched at the ILCA 2020 conference during which Tim Meyer, UCL Cancer Institute, University College in London, UK and Robin Kate Kelley, Associate Professor University of California, San Francisco, USA  have presented the key features as:
  • Interactive therapeutic algorithm
  • Summary of and links to key data that provide the evidence base for current therapy
  • Focussed discussion on clinical decision making according to specific clinical contexts

LEAVE YOUR COMMENTS AND SUGGESTIONS:

Your email address will not be published. Required fields are marked *

Copyright © Society For Clinical Data Management. All Rights Reserved
appstore